We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CBT

News List

Psychotherapy Alone First Line of Treatment for Depressed Youth drugs
August 13, 2019
Cognitive behavioral therapy (CBT) should be the first line of treatment in younger patients with major depressive disorder before clinicians prescribe medication...
FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics pharmafile
December 12, 2018
A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app of its kind for use in the treatment of opioid use disorder (OUD), it has emerged.
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody biospace
March 26, 2018
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554), today announced its commitment to CBT Pharmaceuticals as a leader in the discovery and development of cancer combination therapies.